7 completed, 4 active not recruiting, 4 not yet recruiting, 3 recruiting. 22 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 7, Active not recruiting 4, Not yet recruiting 4, Recruiting 3, Unknown 2, Suspended 1, Terminated 1 |
| Phase 1 | 2 | Not yet recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Servier: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation S243249 600mg, S243249 400mg, S243249 450mg - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 80 | 2026-10-20 | 2026-09-03 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| Ivosidenib as Post-HSCT Maintenance for AML Ivosidenib, Placebo - IDH1 Mutation, Acute Myeloid Leukemia (AML) | Phase 2 | Recruiting | Massachusetts General Hospital | 75 | 2026-01-16 | 2026-10-05 |
| BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients Trifluridine/tipiracil, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 162 | 2025-09-01 | 2025-07-17 |
| PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment Nal-IRI, Ciprofloxacin, Paclitaxel - PDAC - Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 206 | 2025-07-01 | 2025-07-01 |
| Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer Lonsurf, Oxaliplatin, Panitumumab - Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 73 | 2025-03-21 | 2025-12-10 |
| A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Ivosidenib - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic | Phase 2 | Active not recruiting | Servier | 12 | 2023-10-10 | 2025-12-09 |
| Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen - Gastric Adenocarcinoma, Esophagus Adenocarcinoma | Phase 2 | Active not recruiting | UNICANCER | 118 | 2023-06-23 | 2026-07-24 |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer | Phase 2 | Suspended | Gruppo Oncologico del Nord-Ovest | 477 | 2023-05-17 | 2026-02-03 |
| Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML Venetoclax, Decitabine - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Recruiting | Montefiore Medical Center | 91 | 2022-03-23 | 2026-01-05 |
| Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients Trifluridine/Tipiracil, Oxaliplatin - Colorectal Adenocarcinoma, Oesogastric | Phase 2 | Terminated | GERCOR - Multidisciplinary Oncology Cooperative Group | 1 | 2022-02-07 | 2023-09-18 |
| Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma Combination of Lonsurf® and Irinotecan - Cholangiocarcinoma | Phase 2 | Completed | Heinrich-Heine University, Duesseldorf | 28 | 2021-10-28 | 2024-03-27 |
| Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) - Pancreatic Cancer, Metastasis | Phase 2 | Unknown | University of Cologne | 150 | 2021-10-10 | 2024-01-12 |
| TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer trifluridine/tipiracil - Breast Neoplasm, Chemotherapy Effect | Phase 2 | Completed | Borstkanker Onderzoek Groep | 52 | 2020-09-25 | 2026-05-22 |
| Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer Liposomal Irinotecan, Carboplatin, Capecitabine - Esophageal Cancer | Phase 2 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 320 | 2019-05-01 | 2026-08-21 |
| Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma Onivyde, Paclitaxel - Squamous Cell Carcinoma | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 106 | 2019-03-07 | 2025-01-08 |
| Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma Liposomal Irinotecan, Fluorouracil, Folinic Acid - Oncology, Neuroendocrine Carcinoma | Phase 2 | Completed | The Christie NHS Foundation Trust | 58 | 2018-11-13 | 2024-12-30 |
| Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B) - Adenocarcinoma Metastatic, Biliary Tract Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 93 | 2018-01-24 | 2025-10-01 |
| Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies nal-IRI, 5-FU, leucovorin - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic | Phase 2 | Completed | AIO-Studien-gGmbH | 100 | 2017-10-24 | 2022-05-18 |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Prednisone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma | Phase 2 / Phase 3 | Active not recruiting | St. Jude Children's Research Hospital | 790 | 2017-03-29 | 2026-06-17 |
Showing 20 of 22. Sign in to see all of them.
Leukemia, Myeloid, Acute (4) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Leukemia, Myelomonocytic, Chronic (2) · Neoplasm Metastasis (2) · Recurrence (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Squamous Cell (1) · Cardiotoxicity (1) · Colonic Neoplasms (1)
Fluorouracil (7) · Leucovorin (7) · Oxaliplatin (6) · irinotecan sucrosofate (6) · trifluridine tipiracil drug combination (6) · Bevacizumab (2) · Capecitabine (2) · Gemcitabine (2) · Irinotecan (2) · Nivolumab (2) · Paclitaxel (2) · Trastuzumab (2) · ivosidenib (2) · Asparaginase (1) · Bortezomib (1)
France (6) · Germany (6) · United States (3) · Netherlands (2) · Australia (1) · Italy (1) · Japan (1) · United Kingdom (1)
A. Elise van Leeuwen-Stok, PhD (1) · Amir T Fathi, MD (1) · Arndt Vogel, Prof. (1) · Christoph Roderburg, Prof. (1) · Dirk Waldschmidt (1) · Florian Gebauer, MD (1) · Georg Hess, MD (1) · Henning Ebelt, MD (1) · Hiroto Inaba, MD, PhD (1) · Jan M Prins, MD, PhD (1)
PMID 21638157, PMID 31646981, PMID 32029495, PMID 37217885, PMID 37287870, PMID 38762353, PMID 38843469, PMID 38870977, PMID 39316768, PMID 40017682, PMID 40147791, PMID 40876084, PMID 42154791
2016 (2), 2025 (2), 2014 (1), 2019 (1)